Filing Details

Accession Number:
0001562180-17-001968
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-05-16 18:29:42
Reporting Period:
2017-05-15
Filing Date:
2017-05-16
Accepted Time:
2017-05-16 18:29:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1557883 Dermira Inc. DERM Pharmaceutical Preparations (2834) 273267680
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1620520 M. Christopher Griffith C/O Dermira, Inc.
275 Middlefield Road, Suite 150
Menlo Park CA 94025
Svp Head Corp. Dev. & Strategy No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-05-15 1,021 $1.22 46,134 No 4 M Direct
Common Stock Acquisiton 2017-05-15 291 $1.74 46,425 No 4 M Direct
Common Stock Disposition 2017-05-15 1,312 $27.07 45,113 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Options (Right to buy) Disposition 2017-05-15 291 $0.00 291 $1.74
Common Stock Employee Stock Options (Right to buy) Disposition 2017-05-15 1,021 $0.00 1,021 $1.22
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,448 2024-02-06 No 4 M Direct
44,525 2023-01-03 No 4 M Direct
Footnotes
  1. These shares include prior ESPP purchases.
  2. These trades were made pursuant to a Rule 10b5-1 trading plan.
  3. This transaction was executed in multiple trades at prices ranging from $26.64 to $27.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. 25% of the total shares underlying the option vested and became exercisable on February 9, 2015 (the one-year anniversary of the vesting commencement date) and 1/48 of the total shares underlying the option vest and become exercisable each month thereafter, subject to the continuing employment of the Reporting person on the applicable vesting date.
  5. 25% of the total shares underlying the option vested and became exercisable on January 4, 2014 (the one-year anniversary of the vesting commencement date) and 1/48 of the total shares underlying the option vest and become exercisable each month thereafter, subject to the continuing employment of the Reporting person on the applicable vesting date.